Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 2Smoking 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hyperlipoproteinemia Type II 1Hematologic Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

fludarabine 27Azacitidine 26venetoclax 23Cyclophosphamide 22Specimen Handling 21fludarabine phosphate 17Biopsy 16Whole-Body Irradiation 15Mycophenolic Acid 15Busulfan 15Melphalan 14Cytarabine 14Tacrolimus 13Granulocyte Colony-Stimulating Factor 12Decitabine 11Stem Cell Transplantation 10Injections 10Cyclosporine 10decitabine and cedazuridine drug combination 9Sirolimus 9Filgrastim 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7X-Rays 6Idarubicin 6ruxolitinib 5Cyclosporins 5Cladribine 5Methotrexate 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Atorvastatin × 90 days × Clear all
NCT03560882 2026-05-06

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

University of Kansas Medical Center

Phase 1 Active not recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡